Summary & Overview
HCPCS Level II C9034: Intraocular Dexamethasone Injection, 1 mcg
HCPCS Level II code C9034 identifies an intraocular injection of dexamethasone 9% at a 1 mcg dose. This code matters nationally as the use of intraocular corticosteroid preparations is an important component of ophthalmic care for inflammatory and postoperative conditions; accurate coding supports clinical documentation, coverage determinations, and consistent reporting across facilities. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the clinical context for intraocular dexamethasone injections, typical sites of service, and the implications for billing and coverage. The publication presents benchmarks where available, summarizes payer coverage policies and prior authorization tendencies, and highlights relevant coding and service-line considerations for ophthalmology practices and ambulatory surgical centers. The report also outlines common documentation elements that support medical necessity determinations and reimbursement, and it flags areas where payers commonly require additional clinical information. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9034 denotes injection, dexamethasone 9%, intraocular, 1 mcg. This service represents an intraocular administration of dexamethasone at the specified concentration and dose.
-
Service type: Intraocular injection
-
Typical site of service: Ophthalmology clinic, ambulatory surgery center, or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old with diabetic macular edema or retinal vein occlusion who presents to a retinal specialty clinic for intravitreal pharmacologic therapy. The clinician confirms indication, reviews prior ocular surgeries and anticoagulation status, obtains informed consent, and performs a focused ocular examination including visual acuity, intraocular pressure, and anterior segment check. Under sterile technique in an outpatient ophthalmology procedure room or ambulatory surgery center, topical anesthesia and povidone-iodine antisepsis are applied. The provider injects C9034 (intraocular dexamethasone 9%, 1 mcg) into the vitreous cavity via a pars plana approach. Post-procedure, the patient is monitored briefly for pain, vision changes, or elevated intraocular pressure, given aftercare instructions, and scheduled for follow-up to assess treatment response and intraocular pressure within 1–4 weeks.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service on the same day | Use when a significant E/M visit is documented and performed by the same provider on the day of the injection. |
59 | Distinct procedural service | Use if a separate, distinct ocular procedure is performed the same day and must be identified as separate from the injection.